Usa Compression Partners LP (NYSE:USAC), during its Thursday’s current trading session gained 2.77% to $17.41.
USA Compression Partners, LP provides natural gas compression services under term contracts with customers in the oil and gas industry in the United States. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment.
USA Compression Partners, LP (USAC) (the “Partnership”), declared recently the pricing of an underwritten public offering of 4,000,000 common units representing limited partner interests in the Partnership (“common units”) at a public offering price of $19.33 per common unit.
The Partnership intends to use the net proceeds of about $74.4 million from the offering, after discounts, commissions and offering expenses, to reduce indebtedness outstanding under its revolving credit facility and for general partnership purposes. The Partnership will not receive proceeds from any common units sold by the selling unitholders.
UBS Investment Bank, Wells Fargo Securities, Barclays, Goldman, Sachs, & Co., J.P. Morgan, Raymond James and RBC Capital Markets are acting as joint book-running managers for the offering. Regions Securities LLC, Ladenburg Thalmann and MUFG are acting as co-managers.
During Thursday’s Current trade, Shares of Meridian Bioscience, Inc. (NASDAQ:VIVO), lost -0.79% to $17.62.
Meridian Bioscience, Inc., a life science company, develops, manufactures, and distributes diagnostic test kits primarily for certain gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company operates through Diagnostics and Life Science segments.
Meridian Bioscience, Inc. (VIVO) offered the financial community with guidance regarding the Company’s fiscal 2016 net revenues and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2016, administration anticipates net revenue growth of 3% to 5% on a constant currency basis, a net revenue range of $195 to $200 million, and per share diluted earnings to be between $0.86 and $0.90. The per share estimates assume an enhance in average diluted shares outstanding from about 42.1 million at fiscal 2015 year end to 42.2 million at fiscal 2016 year end. The net revenues and earnings guidance offered in this press release is from predictable internal growth and does not comprise net revenue from new products predictable to be launched in 2016, or the impact of any acquisitions the Company might complete during fiscal 2016.
Notes to the Stakeholders:
This article is the intellectual property of www.jbhnews.com. The purpose of penning down this article has been just to share information. Moreover, it is firmly believed that all the information that are revealed in this article are from reliable sources, however, we do not make any representations or warranties whatsoever of any kind, express or implied, as far as the completeness, accurateness, or reliability with respect to this article is concerned.
All the respectable visitors to this website are kindly advised to conduct their own independent research into individual stocks prior to making a purchase decision.
This article contains an advanced information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as well as statements regarding the forseeable frequent growth of the market for the corporation’s products, the corporation’s capability to fund its capital requirement in the close-to term and in the long term; pricing pressures; etc.
Furthermore, any statement that expresses or involves discussions with respect to forecast, expectations, beliefs, strategy, projection, objectives, aims, assumption, or future events or performance may be forward looking statements. In addition, the forward-looking statements are wholly and solely based upon expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. An easy way to identify the forward looking statements is through the use of such words as be expecting, will, foresee, guess, considered, or by statements that indicates certain actions may, could, should/might occur.